|
| Press Releases |
|
 |
|
| Friday, October 30, 2020 |
|
|
Avance Clinical Wins MasterControl 2020 Innovation Excellence Award |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony. more info >> |
|
| Wednesday, October 28, 2020 |
|
|
Biotechs get scalable early to late phase clinical offering from Avance Clinical and Cromos Pharma - announced at Bio-Europe 2020 |
| Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs. more info >> |
|
| Tuesday, September 22, 2020 |
|
|
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions more info >> |
|
| Friday, September 4, 2020 |
|
|
Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease. more info >> |
|
| Wednesday, July 22, 2020 |
|
|
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen. more info >> |
|
| Thursday, July 9, 2020 |
|
|
Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award |
| The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. more info >> |
|
| Tuesday, June 9, 2020 |
|
|
TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020 |
| The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing. more info >> |
|
| Thursday, April 9, 2020 |
|
|
Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis |
| Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time. more info >> |
|
| Thursday, April 2, 2020 |
|
|
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials |
| Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. more info >> |
|
| Friday, March 20, 2020 |
|
|
Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials |
| Australian CRO Avance Clinical said today that Australia's fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
Aug 16, 2025 15:27 HKT/SGT
|
|
|
WL Delicious Announced 2025 Interim Results
Aug 16, 2025 15:25 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 16, 2025 14:55 HKT/SGT
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 16, 2025 14:55 HKT/SGT
|
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products
Aug 16, 2025 14:54 HKT/SGT
|
|
|
How Do AI Workflow Automations Work?
Aug 16, 2025 00:00 HKT/SGT
|
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 15, 2025 23:18 HKT/SGT
|
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT/SGT
|
|
|
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively
Aug 15, 2025 19:11 HKT/SGT
|
|
|
FWD Group marks 12th anniversary with 12 community grants
Aug 15, 2025 14:14 HKT/SGT
|
|
|
TANAKA Holds Press Conference to Commemorate Its 140th Anniversary
Aug 15, 2025 3:00 JST
|
|
|
The 35th Food Expo opens today
Aug 14, 2025 21:05 HKT/SGT
|
|
|
Re-opening of Food Expo and concurrent fairs
Aug 14, 2025 20:05 HKT/SGT
|
|
|
Yuexiu REIT Maintains Overall Operational Stability, Achieves Revenue of Over RMB966 Million 
Aug 14, 2025 19:15 HKT/SGT
|
|
|
Mitsubishi Corporation to acquire shares in Copper World copper mine project in the US
Aug 14, 2025 12:05 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
